You are here

  • Home
  • Archive
  • Volume 10, Issue 12
  • Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells

Article info

Article menu
Basic tumor immunology
Original research
Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells

Authors

  • Martin Thelen Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Diandra Keller Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Jonas Lehmann Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Kerstin Wennhold Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Hendrik Weitz Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Eugen Bauer Institute of Transfusion Medicine, University of Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Birgit Gathof Institute of Transfusion Medicine, University of Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Monika Brüggemann Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Michaela Kotrova Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany PubMed articlesGoogle scholar articles
  • Alexander Quaas Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Christoph Mallmann Department of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Seung-Hun Chon Department of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Axel M Hillmer Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Christiane Bruns Department of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Michael von Bergwelt-Baildon Department of Internal Medicine III, University Hospital, Ludwig Maximilians University Munich, München, GermanyGerman Cancer Consortium (DKTK), Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Maria Alejandra Garcia-Marquez Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  • Hans Anton Schlößer Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, GermanyDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Martin Thelen; martin.thelen{at}uk-koeln.de
View Full Text

Citation

Thelen M, Keller D, Lehmann J, et al
Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells
Journal for ImmunoTherapy of Cancer 2022;10:e005200. doi: 10.1136/jitc-2022-005200

Publication history

  • Accepted November 19, 2022
  • First published December 9, 2022.
Online issue publication 
December 09, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.